Uploaded November 2026 | Updated November 2026, 8 hours ago
As cardiometabolic drug development continues to evolve, researchers face increasing pressure to select preclinical models that generate clinically relevant and actionable data. Yet no single model can fully capture the complexity of human disease, making thoughtful study design and model selection critical for translational success.
This webinar will explore practical strategies for building translational cardiometabolic disease models that align with specific research objectives and therapeutic hypotheses. Key considerations for species selection, disease induction, and study design will be discussed, with an emphasis on understanding how different modeling approaches can impact biological outcomes and translational relevance. The session will also examine the role of genetic modifications, humanized biology, and integrated disease paradigms in addressing increasingly complex research questions.
Through real-world examples, attendees will gain a framework for selecting and combining model components to better reflect human physiology and disease progression. Participants will leave with practical considerations for designing preclinical studies that support decision-making across discovery, translational research, and drug development programs in obesity, metabolic disease, cardiovascular disease, and related cardiometabolic indications.
Learning Objectives:
- Compare the advantages and limitations of different species, disease induction approaches, and model systems for cardiometabolic disease research.
- Evaluate how genetic modifications, target humanization, and study design choices influence translational relevance and experimental outcomes.
- Design a translational preclinical strategy that aligns model selection with a specific therapeutic hypothesis or drug development objective.
Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.
Group viewing options are available - see our CE credit page for more information
Speakers:
Laura Griffin, PhD - Portfolio Manager, CVMD, Taconic Biosciences
Sarah Sterlace, PhD - Senior Director, Neurobiology Portfolio
As cardiometabolic drug development continues to evolve, researchers face increasing pressure to select preclinical models that generate clinically relevant and actionable data. Yet no single model can fully capture the complexity of human disease, making thoughtful study design and model selection critical for translational success.
This webinar will explore practical strategies for building translational cardiometabolic disease models that align with specific research objectives and therapeutic hypotheses. Key considerations for species selection, disease induction, and study design will be discussed, with an emphasis on understanding how different modeling approaches can impact biological outcomes and translational relevance. The session will also examine the role of genetic modifications, humanized biology, and integrated disease paradigms in addressing increasingly complex research questions.
Through real-world examples, attendees will gain a framework for selecting and combining model components to better reflect human physiology and disease progression. Participants will leave with practical considerations for designing preclinical studies that support decision-making across discovery, translational research, and drug development programs in obesity, metabolic disease, cardiovascular disease, and related cardiometabolic indications.
Learning Objectives:
- Compare the advantages and limitations of different species, disease induction approaches, and model systems for cardiometabolic disease research.
- Evaluate how genetic modifications, target humanization, and study design choices influence translational relevance and experimental outcomes.
- Design a translational preclinical strategy that aligns model selection with a specific therapeutic hypothesis or drug development objective.
Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.
Group viewing options are available - see our CE credit page for more information
Speakers:
Laura Griffin, PhD - Portfolio Manager, CVMD, Taconic Biosciences
Sarah Sterlace, PhD - Senior Director, Neurobiology Portfolio
